and improve patient satisfaction and outcome 5 . Early interaction between mother and infant, which is critical to bonding, is optimised if the woman is comfortable and free of drug-induced side-effects, particularly sedation, nausea and vomiting. In addition, the breast milk transfer of opioid has the potential to impair the establishment of breastfeeding 6 .
Unless contraindicated, both paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) are often used after caesarean delivery, based on an assumption of similar benefits and the knowledge that they are considered safe to use during human lactation 7 . A possible but unestablished benefit is that reduction in acute postoperative pain might reduce the risk of chronic wound pain 8, 9 . After caesarean delivery under regional anaesthesia, there is substantial evidence supporting reduced opioid requirements or improved analgesia when NSAIDs are given with systemic opioids [10] [11] [12] [13] [14] [15] and some support Anaesthesia and Intensive Care, Vol. 42, No. 1, January 2014 for cyclooxygenase-2 (COX-2) inhibitors 16 , the latter drugs being preferable for those obstetric patients for whom traditional NSAIDs are contraindicated due to peptic ulceration, bleeding risk or asthma. However, studies of NSAIDs, including COX-2 inhibitors such as valdecoxib or celecoxib, as adjuncts to neuraxial opioids, report mixed and conflicting findings, some suggesting benefit [17] [18] [19] [20] and others none [21] [22] [23] [24] [25] . There is no evidence to support paracetamol after caesarean delivery, the only placebo-controlled trial reporting no significant effect on systemic morphine use by propacetamol alone or in combination with diclofenac 12 . Further investigation of paracetamol is nevertheless important, because it is very rarely contraindicated and has an excellent side-effect profile.
We tested the hypothesis that paracetamol, COX-2 inhibitors or the combination of both would result in opioid dose-sparing and possibly improve analgesia in patients using patient-controlled epidural analgesia (PCEA) after elective caesarean delivery.
METHODS
This randomised, four-arm parallel group, double blind, double-dummy placebo-controlled clinical trial was conducted at the King Edward Memorial Hospital for Women between February 2010 and February 2012. The trial received institutional ethical approval from the Women and Newborn Health Service Human Ethics Committee (number 1736/EW, approved 6 October 2009) and was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12611000345987). American Society of Anesthesiologists class 1 or 2 women undergoing elective caesarean section with a Pfannenstiel incision under combined spinal-epidural anaesthesia were recruited at antenatal pre-admission clinics and the maternal-foetal assessment unit, birthing unit or ward, as appropriate, and gave written informed consent. Exclusion criteria were the preoperative use of opioid medication, a contraindication to study drug or planned postoperative analgesic drugs, preoperative pruritus or nausea, failure to identify the subarachnoid space or to catheterise the epidural space at the time of combined spinal-epidural anaesthesia, unintentional dural puncture with the epidural needle or catheter, requirement for intraoperative opioid via any route or conversion to general anaesthesia.
A randomisation sequence for four groups in a 1:1:1:1 ratio was generated by the hospital Pharmacy Department using a computer-generated random number sequence. Allocation was by selection of the next sealed and coded study drug package and occurred intraoperatively. The package, containing coded solutions and bottles of drugs, was opened and the study regimen started immediately after delivery. The drugs consisted of intravenous (IV) solutions (200 ml for infusion over 15 minutes or 2 ml for bolus injection after delivery) and per os (PO) capsules of identical appearance (for administration after surgery). The study groups received saline placebo solutions and capsules (group C, control); parecoxib 40 mg IV followed by celecoxib 400 mg PO at 12 hours and appropriate placebos (group PC); paracetamol 2 g IV followed by paracetamol 1 g PO at 6, 12 and 18 hours and appropriate placebos (group PA); or parecoxib 40 mg IV and paracetamol 2 g IV, followed by paracetamol 1 g PO at 6, 12 and 18 hours and celecoxib 400 mg PO at 12 hours (group PCPA).
All participants received 16-gauge Tuohy and 27-gauge pencil-point needle (CSEcure ® , Portex, Smiths Medical Australia, Bella Vista, New South Wales) combined spinal-epidural anaesthesia at a low lumbar intervertebral space, with hyperbaric bupivacaine 0.5% w/v 2.1 to 2.5 ml plus fentanyl 15 µg. Intraoperative pain was managed with inhaled nitrous oxide and epidural, intraperitoneal or wound local anaesthetic, as required. All patients had consented to at least 24 hours of postoperative pethidine PCEA, using a disposable pump (Go Medical Industries, Perth, Western Australia) containing pethidine 300 mg in 60 ml normal saline and delivering 4 ml (20 mg) on demand at a 15-minute lockout interval. If the verbal numerical rating score (VNRS) for pain was >6 with movement or >3 at rest at any time, supplementary analgesia was available in the form of immediate-release tramadol 50 to 100 mg PO two-hourly on demand (maximum dose 600 mg across 24 hours). Thereafter, analgesia was at the discretion of the attending anaesthetist or acute pain service. Postoperative pruritus was treated with IV ondansetron 4 mg six-hourly on demand or, if this was ineffective, IV naloxone 50 µg hourly on demand.
All observers were blinded to study group allocation. Baseline data were collected within 24 hours of the scheduled start of surgery and included age, American Society of Anesthesiologists status, weight, height, parity, gravidity, gestation, number of previous caesarean deliveries, preoperative quality of recovery (QoR) score (0 to 18 QoR, a validated postoperative recovery score assessing various symptoms and functionality) 26 and the opioid-related Symptom Distress Questionnaire (SDQ) score (0 to 36 SDQ, a validated tool that assesses the clinical meaningfulness of postoperative opioid-related symptoms) 27 .
The time of intrathecal drug injection and the drug doses, the time to completion of surgery and the use of intraoperative analgesics was noted. Postoperative data included the time of study solution administration; the 0 to 10 VNRS pain scores at rest and movement at 6, 12, 24 and 48 hours; the VNRS sedation scores at the same times; and the area under the curve (AUC) for rest and movement pain scores over 0 to 24 hours. At 24 hours, patients were questioned regarding the presence of gastrointestinal upset, nausea or epigastric pain; asked about satisfaction with analgesia (0 to 10 VNRS and ratings of excellent, good, fair or poor); and asked about severity of overall nausea, sedation and pruritus (VNRS). They completed the QoR score, the opioidrelated SDQ score and a Modified Brief Pain Inventory (short-form). The medical record was checked to determine use of additional analgesics and antiemetic drugs. At 48 hours, pain and sedation scores were recorded and the presence of urinary retention post-catheter removal or observed respiratory depression (respiratory rate <8 breaths per minute or sedation score of 3 representing 'difficult to rouse') assessed.
Recruited n=138
Group C Planned exclusions n=9
Randomised and allocated to placebo n=23
Group PC Planned exclusions n=5
Randomised and allocated to parecoxib, celecoxib n=30
Group PA Planned exclusions n=3
Randomised and allocated to paracetamol n=32
Follow-up

Analysis n=111
Group C Lost to follow-up n=0
Group PC Lost to followup n=0
Group PA Lost to followup n=0
Group PCPA Lost to follow-up n=0
Group C Analysed n=23
Major protocol violations n=3
Group PC Analysed n=30
Major protocol violations n=5
Group PA Analysed n=32
Major protocol violations n=4
Group PCPA Analysed n=26
Major protocol violations n=5
Assessed for eligibility n=537 Recruited n=144 Not available due to re-scheduling or loss to follow-up n=6
Enrolment
Group PCPA Planned exclusions n=10
Randomised and allocated to parecoxib, celecoxib and paracetomol n=26 Figure 1 : CONSORT participant flow chart. C=control, PC=parecoxib 40 mg IV followed by celecoxib 400 mg per os at 12 hours and appropriate placebos, PA=paracetamol 2 g IV followed by paracetamol 1 g per os at 6, 12 and 18 hours and appropriate placebos, PCPA=parecoxib 40 mg IV and paracetamol 2 g IV, followed by paracetamol 1 g per os at 6, 12 and 18 hours and celecoxib 400 mg per os at 12 hours.
CONSORT=consolidated standard of reporting trials. 
Sample size calculation and statistical analysis
The sample size was generated using Power and Sample Size (PASS 2008) by the biostatistical author (EAN). The primary study endpoint was epidural pethidine consumption during the first 24 hours. The main secondary outcomes were the 0 to 24 hour AUC pain scores with movement, the quality of recovery score and the SDQ score. A one-way design with 84% power to detect a difference of 25% between the control and any treatment group required a group sample size of 26, assuming mean control pethidine use of 360 mg with a standard deviation of 122 mg 28 . To allow for withdrawals, the sample size per group was increased to 30 (total sample size 120). This also gave a power of 99% to detect a two-point difference between groups in the movement pain score at 24 hours.
An intention-to-treat analysis was performed but the primary outcome was also measured in a per protocol analysis in which major violations were excluded. Major violations were defined as patients who did not receive all the allocated study drugs or those in whom alternative postoperative analgesia was given on the first postoperative day, usually because the epidural catheter dislodged prematurely. Continuous data were summarised using median, interquartile range (IQR) and range and categorical data using frequency distributions. Univariate comparisons of continuous outcomes between treatment groups were conducted using Kruskal-Wallis tests. Pair-wise comparisons between control and treatment groups were made with an overall family-wise type 1 error controlled at alpha 0.05. The chi-square test was used for comparisons of categorical outcomes. AUC for rest and movement pain to 24 hours was calculated using the trapezium rule; missing data at some time points were imputed by carrying the last observation 
RESUlTS
In the antenatal period we identified 144 women, of whom six did not proceed to surgery as planned or were lost to follow-up, usually because of non-elective surgery. Of these 138 women who gave consent, 27 subsequently met exclusion criteria, mainly due to failure of a component of the combined spinalepidural technique, so were not randomised to a group. This left 111 participants who commenced a study drug and constituted the intention-to-treat analysis (Figure 1 ). Of 37 protocol violations within this cohort (mainly failure to complete 24 hours of PCEA), 17 (15%) had major violations such as failure to receive all study drugs or unplanned analgesic administration in the first 24 hours. The number of violations or major violations did not differ among the groups (P=0.91 and 0.63 respectively).
The baseline characteristics of patients did not differ between groups (Table 1) .
For the primary outcome of epidural pethidine consumption in the first 24 hours of PCEA use, there was no difference between groups, based on either the intention-to-treat or per protocol analyses ( Table 2) .
Among the main secondary outcomes, the 0 to 24 hour AUC for movement pain did not differ between groups (Table 2 and Figure 2 ). The 24-hour QoR score and opioid-related SDQ score did not differ between groups.
The 24 and 48 hour pain scores at rest or with movement did not differ between groups. The AUC for rest pain differed among treatments (P=0.019), with pair-wise comparisons indicating that group Data represent median (IQR) or N (%). ASA=American Society of Anesthesiologists, BMI=body mass index, CD=caesarean delivery, C=control, PC=parecoxib 40 mg IV followed by celecoxib 400 mg orally at 12 hours and appropriate placebos, PA=paracetamol 2 g IV followed by paracetamol 1 g orally at 6, 12 and 18 hours and appropriate placebos, PCPA=parecoxib 40 mg IV and paracetamol 2 g IV, followed by paracetamol 1 g orally at 6, 12 and 18 hours and celecoxib 400 mg orally at 12 hours.
PA reported a significantly higher score (median 44, IQR 25 to 68) compared with group C (median 30, IQR 9 to 42) (P=0.011). Group PC (median 24, IQR 11 to 37) and Group PCPA (median 32, IQR 12 to 47) did not differ from group C (P=0.808 and 0.501 respectively). The scores for the Modified Brief Pain Inventory (data not shown) did not differ between the groups, with the exception of the response relating to 'pain now' (at 48 hours), which was higher in group PA (38% of scores within the range 4 to 10, compared with 18% in group C, 13% in group PC and 12% in group PCPA, P=0.047). The incidence of tramadol use as further supplementary analgesia differed significantly between treatment groups (P=0.004), with group PCPA showing the lowest incidence (23% versus 48%, 70% and 58% in groups C, PC, and PA respectively). The total dose of tramadol given in the first 24 hours differed significantly between treatments (Table 2) , with pair-wise comparisons indicating group PCPA used less than groups PC (P=0.006) and PA (P=0.042) but not group C (P=0.39).
Neither the incidence of nausea, which was low in all groups (range 9% to 19%), nor the severity of sedation, differed between groups at any time point (data not shown, P=0.696 and 0.981 respectively). The incidence and severity of pruritus was significantly greater in all treatment groups (groups PC, PA and PCPA) compared with the control group 22, 22, 18 in groups C, PC, PA and PCPA respectively). Values are median (IQR ± range) and P values are across group comparisons. * P values <0.005 considered significant using a Bonferroni correction (α=0.05/10). # group PA significantly greater than group C (P=0.01). ^ group PCPA lower than groups PA (P=0.042) and PC (P=0.006). h=hours, PCEA=patientcontrolled epidural analgesia, C=control, PC=parecoxib 40 mg IV followed by celecoxib 400 mg orally at 12 hours and appropriate placebos, PA=paracetamol 2 g IV followed by paracetamol 1 g orally at 6, 12 and 18 hours and appropriate placebos, PCPA=parecoxib 40 mg IV and paracetamol 2 g IV, followed by paracetamol 1 g orally at 6, 12 and 18 hours and celecoxib 400 mg orally at 12 hours.
Anaesthesia and Intensive Care, Vol. 42, No. 1, January 2014 (69%, 69% and 62% versus 30%, P=0.016: median (IQR) intensity 3 (0 to 5), 2 (0 to 5), 4 (0 to 6) versus 0 (0 to 3), P=0.025). There was one case of urinary retention requiring re-catheterisation in each of groups PA and PCPA, and one case of respiratory depression that did not require naloxone in group C. Maternal satisfaction with the analgesic regimen did not differ between groups (good or excellent in 86%, 97%, 100% and 92% of groups C, PC, PA and PCPA respectively, P= 0.15).
DISCUSSION
This study indicates that when pethidine PCEA is used as the primary analgesic method after caesarean delivery under spinal anaesthesia, the addition of parecoxib then regular celecoxib, regular paracetamol administration, or a combination of these non-opioid analgesics does not reduce epidural pethidine requirements or improve dynamic pain scores in the first 24 hours after surgery.
The absence of a dose-sparing effect on opioid consumption in this study may reflect differences between epidural and systemic opioid analgesia. The epidural route leads to consumption of approximately 50% less pethidine than an intravenous approach, despite higher quality analgesia 28 . Several studies that found prolonged or better quality analgesia with the inclusion of non-opioid adjuncts were conducted using a primary analgesic technique that achieved only moderate pain relief, whether from intravenous morphine patient-controlled analgesia, low-dose epidural morphine or spinal morphine 15, 17, 18, 20 . One study found that it was necessary to use both paracetamol and a NSAID to achieve a reduction in intravenous patient-controlled morphine requirements, although the opioid side-effect profile was not altered 29 . Others have reported epidural opioid dose reduction but no improvement in clinical outcomes 22, 23 .
Our study contrasts with a study that found that analgesia 36 hours after a dose of spinal morphine 200 µg was improved by the addition of oral naproxen 30 , presumably because the effect of spinal morphine had dissipated by this time. In contrast, most participants in our study continued to use PCEA or systemic tramadol after 24 hours, likely masking any benefit from the non-opioid analgesics.
Selective COX-2 inhibitors, such as parecoxib and celecoxib, are a potentially useful alternative to traditional NSAIDs after caesarean delivery because they lack significant effects on gastric mucosa and platelet function 31 and are relatively safe in asthma 32 . COX-2 inhibitors appear to have similar analgesic efficacy to non-selective NSAIDs 31 and, when used as adjuncts to intravenous morphine after caesarean delivery, both parecoxib and celecoxib result in opioid dose-sparing effects 16, 33 . However, as in this study, after neuraxial opioid (spinal morphine) neither intravenous ketorolac, regular oral valdecoxib nor celecoxib are of benefit 21, 24, 25 . It is possible that alternative dosing regimens (for example repeated parecoxib dosing or celecoxib 400 mg BD) would have improved efficacy, given that these higher doses may be more effective for some patients 34, 35 and that the pharmacokinetics of parecoxib and celecoxib in pregnancy are unknown.
Paracetamol has an excellent side-effect profile and does not worsen platelet function when combined with parecoxib 36 . Despite opioid dose-sparing effects in non-obstetric surgical populations, there is no evidence for fewer or less severe opioid-induced side-effects or improved patient satisfaction 1, 2, 37 . A single study which lacked a control group suggested oral paracetamol and ibuprofen were comparable adjuncts to intravenous morphine after caesarean delivery 38 . However, only a third of patients get approximately four hours of effective analgesia after a single IV dose of paracetamol 1 g and among those with moderate baseline pain after caesarean delivery, paracetamol does not improve analgesic efficacy 12, 29, 39 . Patient satisfaction is lower than that after NSAIDs 12, 29 . In this study we attempted to optimise the therapeutic Figure 2 : Area under the curve for rest and movement pain scores in the first 24 hours, by treatment group. PC=parecoxib 40 mg IV followed by celecoxib 400 mg orally at 12 hours and appropriate placebos, PA=paracetamol 2 g IV followed by paracetamol 1 g orally at 6, 12 and 18 hours and appropriate placebos, PCPA=parecoxib 40 mg IV and paracetamol 2 g IV, followed by paracetamol 1 g orally at 6, 12 and 18 hours and celecoxib 400 mg orally at 12 hours. effect of paracetamol by IV loading with 2 g, before regular oral dosing, this being a recommended and safe strategy 40 . Despite this, lack of benefit was consistent with low baseline pain scores during PCEA and is less likely explained by subtherapeutic plasma concentrations, despite peak and trough concentrations being lower in pregnant women 41 .
The use of both paracetamol and NSAIDs in non-obstetric surgical settings improves analgesia compared with either drug alone 3 , but in our study failed to show a clinically important benefit, except arguably in a small proportion of patients for whom it prolonged the time before rescue analgesia during PCEA. Reduction in rescue analgesia after parecoxib is consistent with meta-analysis in the acute postoperative setting 42 and also with studies showing longer spinal morphine analgesia post-caesarean when NSAIDs are given 19, 20 . The effect of dual non-opioid adjuncts in this study was not clinically important and did not appear to alter recovery, opioid-related symptoms or satisfaction, although the study was not designed to detect a difference in these outcomes or in costs associated with the nonopioid combination versus the rescue analgesic, tramadol. If the combination does reduce rescue analgesia, the clinician must decide whether routine use with PCEA is justified or whether it is more appropriate to omit these drugs and supplement patients as necessary.
The increased incidence of pruritus in our treatment groups was unexpected and is unexplained. It has been suggested that NSAIDs can reduce pruritus through opioid dose reduction, but a previous study using celecoxib found no effect on the incidence or severity of pruritus among women receiving intrathecal morphine 24 .
The study has several limitations. The results do not pertain to other peripartum surgical procedures or to outcomes when different primary analgesic methods or higher doses of the non-opioid drugs are provided after caesarean delivery. It is possible the dose regimens for the COX-2 inhibitors and for paracetamol were inadequate for this obstetric population--all premarketing pharmacokinetic and efficacy studies were performed in non-pregnant patients. There were a number of protocol violations, some due to noncompliance with regular oral medication and many as a result of early dislodgement of the epidural catheter. This reflects the pragmatic nature of this clinical trial, and despite deviations from the standardised protocol occurring frequently, the treatment groups were not affected differentially and the inferences of the study were unchanged. Finally, the study was not adequately powered to detect differences for all treatment and control group comparisons; however, evaluating a larger sample size would be unlikely to change conclusions given the minor differences in overall pethidine use.
In summary, the results of this study do not support the routine regular administration of COX-2 inhibitors and paracetamol, either alone or in combination, when a patient-controlled epidural opioid analgesic method is used after spinal anaesthesia for caesarean delivery.
